中文摘要：

心律失常是導(dǎo)致猝死的主要因素之一，而猝死是一個(gè)未滿足的重大醫(yī)療需求。由于右心室（RV）功能障礙會(huì)增加猝死風(fēng)險(xiǎn)，我們?cè)谛∈笾醒芯苛藢?duì)右心室壓力應(yīng)激的反應(yīng)。在肺動(dòng)脈縮窄引起的壓力超負(fù)荷后積聚在右心室的免疫細(xì)胞中，荷蘭Liposoma巨噬細(xì)胞細(xì)胞清除劑清除單核巨噬細(xì)胞會(huì)導(dǎo)致嚴(yán)重心律失常引發(fā)的猝死。我們發(fā)現(xiàn)，心臟巨噬細(xì)胞通過通過縫隙連接促進(jìn)心肌細(xì)胞間的通信，對(duì)維持心臟沖動(dòng)傳導(dǎo)至關(guān)重要。心臟巨噬細(xì)胞產(chǎn)生的兩性表皮生長(zhǎng)因子（AREG）是調(diào)控心肌細(xì)胞中連接蛋白43磷酸化及轉(zhuǎn)位的關(guān)鍵介質(zhì)。從巨噬細(xì)胞中刪除Areg會(huì)導(dǎo)致縫隙連接紊亂，進(jìn)而在急性應(yīng)激狀態(tài)下（包括右心室壓力超負(fù)荷和β-腎上腺素能受體激動(dòng)）引發(fā)致命性心律失常。這些結(jié)果表明，來自心臟常駐巨噬細(xì)胞的AREG是心臟沖動(dòng)傳導(dǎo)的關(guān)鍵調(diào)節(jié)因子，并可能成為預(yù)防猝死的有效治療靶點(diǎn)。

英文摘要：

Cardiac arrhythmias are a primary contributor to sudden cardiac death, a major unmet medical need. Because right ventricular (RV) dysfunction increases the risk for sudden cardiac death, we examined responses to RV stress in mice. Among immune cells accumulated in the RV after pressure overload-induced by pulmonary artery banding, interfering with macrophages caused sudden death from severe arrhythmias. We show that cardiac macrophages crucially maintain cardiac impulse conduction by facilitating myocardial intercellular communication through gap junctions. Amphiregulin (AREG) produced by cardiac macrophages is a key mediator that controls connexin 43 phosphorylation and translocation in cardiomyocytes. Deletion of Areg from macrophages led to disorganization of gap junctions and, in turn, lethal arrhythmias during acute stresses, including RV pressure overload and β-adrenergic receptor stimulation. These results suggest that AREG from cardiac resident macrophages is a critical regulator of cardiac impulse conduction and may be a useful therapeutic target for the prevention of sudden death.

論文信息：

論文題目：Cardiac macrophages prevent sudden death during heart stress

期刊名稱：Nature Communications

時(shí)間期卷：12, Article number: 1910 (2021)

在線時(shí)間：2021年3月26日

DOI：doi.org/10.1038/s41467-021-22178-0

產(chǎn)品信息：

貨號(hào)：CP-005-005

規(guī)格：5ml+5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱：Clodronate Liposomes& Control liposomes

辦事處：Target Technology(靶點(diǎn)科技)

Clodronate Liposomes氯膦酸鹽脂質(zhì)體清除肝臟和腫瘤巨噬細(xì)胞，疾病模型為：肺動(dòng)脈環(huán)縮術(shù)(pulmonary artery banding, PAB)模型。Pulmonary artery banding (PAB) 是通過環(huán)束帶限制肺動(dòng)脈血流的姑息性手術(shù)，主要用于治療先天性心臟病，如室間隔缺損、大動(dòng)脈轉(zhuǎn)位等伴隨過度肺血流的疾病。 ?原理: 該手術(shù)通過聚四氟乙烯帶環(huán)束肺動(dòng)脈主干，降低肺動(dòng)脈壓力和血流量，緩解心臟負(fù)擔(dān)。早期作為復(fù)雜先心病分期治療的過渡手段，現(xiàn)僅用于多發(fā)性室間隔缺損、合并主動(dòng)脈縮窄等特殊病例。荷蘭Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes見刊于Nature Communications：心臟巨噬細(xì)胞在心臟壓力期間防止猝死。

Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體的材料和方法文字描述：

Animal studies

Male C57BL6/J mice were purchased from CLEA Japan and Jackson Laboratory and maintained on a standard mouse chow diet under sterile barrier conditions, on a 12-h light-dark cycle with 18–23?°C and 40–60% humidity. Male Areg homozygous null (Areg?/?) mice were backcrossed to C57BL6/J mice over ten generations. Rag2?/?, Cd4?/?, and Cd8a?/? mice were purchased from Taconic (Germantown, NY). The genotypes of all mice were determined using genomic PCR. The isoproterenol challenge entailed bolus administration of isoproterenol (Sigma) 5?mg/kg intraperitoneally under constant ECG recording. Clodronate liposomes and control liposomes were purchased from LIPOSOMA B.V. A total of 10?μl of clodronate or control liposome solution per gram of mouse were intravenously administrated 24?h before PAB. After the first administration of clodronate or control liposomes, the same volume of liposomes was also administrated every 7 days for long term depletion, per the manufacturer’s instructions. All protocols for animal experiments were approved by the Animal Care and Use Committee of the University of Tokyo.

Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體的材料和方法文獻(xiàn)截圖：